Thryv Therapeutics licenses structurally distinct SGK1 inhibitors to expand into Parkinson's and Alzheimer's disease
核心洞察
Thryv Therapeutics (搜索) secured an exclusive, worldwide license to a structurally distinct class of SGK1 (搜索) inhibitors from CSIC, UAM, and FUAM, effective July 1, 2026, covering all fields of use with sublicensing rights.
The licensed chemotype is chemically independent from Thryv's cardiovascular scaffold, enabling optimization specifically for central nervous system penetration in Parkinson's disease (搜索), Alzheimer's disease (搜索), and related tauopathies.
Thryv targets a first development candidate nomination from the new series in 2027, while its lead asset THRV-1268 advances in a Phase II/III Long QT Syndrome Type 2 (搜索) study and a planned Phase IIa heart failure trial.
Montréal-based Thryv Therapeutics (搜索) Inc. has licensed an exclusive, worldwide patent and know-how rights to a structurally distinct class of SGK1 (搜索) inhibitors from Spain's Consejo Superior de Investigaciones Científicas (CSIC), the Universidad Autónoma de Madrid (UAM), and the Fundación de la Universidad Autónoma de Madrid (FUAM). The agreement extends Thryv's serum- and glucocorticoid-regulated kinase 1 (SGK1) inhibitor platform into Parkinson's disease (搜索), Alzheimer's disease (搜索), and related neurodegenerative disorders. Effective July 1, 2026, the deal grants Thryv rights across all fields of use in all territories, with sublicensing rights. Financial terms were not disclosed.
The licensed series represents a chemically independent scaffold from the compounds underpinning Thryv's existing cardiovascular pipeline — a distinction the company said gives it the ability to optimize chemistry specifically for central nervous system penetration rather than adapting compounds designed for cardiac indications. No development candidate from the CSIC/UAM series has yet been nominated; Thryv said it is targeting a first candidate nomination in 2027.
A second chemotype for CNS-directed development
The practical value of a second, distinct chemotype is that it lets Thryv separate optimization tracks. Its current molecules, built from a library of more than 500 synthesized analogs on the original scaffold, are advancing toward cardiac indications. The new CSIC/UAM series was never designed to compete with that chemistry; it was designed from the start to cross into the central nervous system, where the cardiac compounds were not built to go.
The CSIC/UAM chemistry originated from a collaboration spanning medicinal chemistry, cardiovascular pharmacology, neurobiology, and vascular pharmacology groups across the two institutions. The research groups behind the licensed compounds span medicinal chemistry, neurobiology, cardiovascular biology, and vascular pharmacology at CSIC's Centro de Investigaciones Biológicas Margarita Salas and UAM's Institute for Biomedical Research. That breadth matters because CNS drug development typically requires the chemistry and the disease biology to be co-developed from early stages.
The patent claims cover both neurodegenerative and cardiovascular indications, giving Thryv broad optionality from a single transaction without field-of-use restrictions — a structure that is unusual for academic licenses at this stage, which are more commonly limited to a defined therapeutic area.
SGK1 biology and disease relevance
SGK1 (搜索) has published links to tau phosphorylation, misfolded protein handling, neuroinflammatory signaling, and FOXO- and NRF2-dependent stress responses, all pathways with direct relevance to Parkinson's and Alzheimer's. Neither disease has an approved therapy that addresses the kinase biology Thryv is targeting.
Approved options for Alzheimer's disease (搜索) remain limited and recently expanded to include lecanemab maintenance dosing; for Parkinson's, the treatment toolkit has been largely stable, with the FDA's March 2026 labeling action on levodopa/carbidopa the most recent notable regulatory move.
Advancing the cardiovascular pipeline in parallel
The deal arrives as Thryv's lead asset, THRV-1268, an orally available selective SGK1 (搜索) inhibitor, is advancing on two fronts. The company commenced patient dosing in Wave II, a multicenter Phase II/III study in genetically confirmed Long QT Syndrome (LQTS) Type 2, in April 2026 and received FDA Fast Track Designation for THRV-1268 in that setting. A Phase IIa study in heart failure with reduced ejection fraction, ASPIRE-HF, is planned to follow. Thryv received FDA IND clearance for THRV-1268 in heart failure and atrial fibrillation in September 2025.
The CSIC/UAM license is Thryv's second academic in-license of an SGK1 (搜索) scaffold. The company was founded on SGK1 inhibitor chemistry and built its cardiovascular pipeline through independent medicinal chemistry on that original series. Adding a second independent chemotype allows parallel development tracks without the two programs competing for the same chemical optimization resources.
No other company currently has an SGK1 (搜索) inhibitor in clinical trials for cardiovascular or neurodegenerative disease based on publicly available records. The concrete marker to track now is whether Thryv nominates a development candidate from the new series on its 2027 timeline, since that decision will signal whether the CNS program moves from platform expansion into something with a clinical path.